Compare AbCellera Biologics Inc (ABCL) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Mattel Inc — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Mattel Inc trades at $13.03 (market cap $3.90B). The key difference: Mattel Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | MAT | |
|---|---|---|
Market Cap | $2.35B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $22.16 |
52-Week Low | $2.78 | $13.05 |
Enterprise Value | $1.99B | $5.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Mattel (MAT) trades at $13.42, up 0.6% on the day, with a bearish technical signal but bullish oscillators like RSI suggesting potential oversold conditions. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results pending. Financially, it maintains solid profitability with a 9.27% net margin and attractive valuation ratios, including a P/E of 8.36. Recent news highlights brand expansions and a shareholder push for strategic alternatives.
The outlook is cautiously optimistic, supported by strong brand portfolio and analyst consensus, but risks include declining cash flows and competitive pressures. Investment opportunities lie in potential strategic moves and undervaluation, while key risks involve execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
